Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Evolent Health, Inc. (EVH)

Evolent Health Q1 revenue rises to $496.2 million; net loss narrows to $26.6 million

Positive Impact 3 of 5 earnings Written later

Evolent Health reported first-quarter 2026 revenue of $496.2 million, up from $483.6 million a year earlier, and a net loss attributable to common shareholders of $26.6 million, or $0.24 per share, versus $72.3 million, or $0.63 per share, a year earlier. Adjusted EBITDA fell to $22.1 million from $36.9 million, and the company reiterated its full-year 2026 revenue and Adjusted EBITDA guidance.

Key points

  • Q1 2026 revenue was $496.2 million versus $483.6 million in Q1 2025; net loss narrowed to $26.6 million from $72.3 million.
  • Adjusted EBITDA was $22.1 million (4.4% margin) versus $36.9 million (7.6% margin) a year earlier.
  • Full-year 2026 guidance was reiterated at $2.4 billion to $2.6 billion in revenue and approximately $110 million to $140 million in Adjusted EBITDA.

The filing

CompanyEvolent Health, Inc. (EVH)
Form8-K, current report
Filed with the SECMay 7, 2026, 7:05 AM ET
Accession number0001628908-26-000031

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.